ItalyItaly

Regions take anti-GMO stand

03.11.2010

Rome – When it comes to GMOs, the gap between Italy’s federal government and its regions that has marked the country for years is rapidly widening into a gulf. The latest rupture was on display at the October session of the Conferenze Stato Regioni ed Unificata. The body’s 22 members represent the regions and autonomous provinces of Italy, and the conference is where the provinces struggle to be heard at the national level. On October 7th, the message was clear. The regional chiefs called on Italian Minister for Agriculture Giancarlo Garlan to impose a full moratorium on the two GMO varieties licensed for cultivation in Italy and the EU – Monsanto’s MON810 and BASF’s amflora potato. The provinces have rejected Garlan’s proposed guidelines for coexistence. After an Italian farmer in Friuli-Venezia Giulia broke a de facto national moratorium on biotech crops that has been in effect since 1998, Garlan instructed the country’s national research body (CRA – Centro Ricerche Agricoltura) to carry out additional tests in order to feed into work on establishing coexistence guidelines. With the regions almost unilaterally opposing coexistence – only Lombardy cast no vote – Garlan said he is now trying to think of an alternative way to “ensure the progress of science and the liberty of research.”

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-italy/article/regions-take-anti-gmo-stand.html

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.80 EUR4.00%
  • MAGFORCE6.45 EUR3.20%
  • CO.DON2.50 EUR2.88%

FLOP

  • WILEX2.10 EUR-7.08%
  • CYTOS0.26 CHF-3.70%
  • ADDEX4.03 CHF-1.71%

TOP

  • WILEX2.10 EUR162.5%
  • MAGFORCE6.45 EUR16.2%
  • BB BIOTECH136.80 EUR6.5%

FLOP

  • VITA 343.89 EUR-22.4%
  • MOLOGEN7.80 EUR-19.3%
  • PAION2.42 EUR-16.6%

TOP

  • SANTHERA67.95 CHF3247.3%
  • PAION2.42 EUR231.5%
  • CO.DON2.50 EUR212.5%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-67.2%
  • THERAMETRICS0.08 CHF-50.0%

No liability assumed, Date: 18.08.2014


Current issue

All issues

Product of the week

Products